An FDA panel voted yes on BPC-157. The FDA’s own scientists couldn’t say what it is.

What it is

BPC-157 is a synthetic chain of 15 amino acids based on a fragment of a protein found in human gastric juice. In its drug-development years it went by Bepecin and PL 14736. It is sold for tendon, ligament, muscle and gut repair, usually as a self-injected vial and often blended with TB-500. A 2025 systematic review noted that Google searches for “BPC-157” hit an all-time high in June 2024, alongside more than 50 million tagged video views on YouTube and TikTok. By volume of interest, it is the peptide market’s flagship.

Where it started

Almost everything known about BPC-157 comes from animals, and most of it from one lab. Researchers in Zagreb first described it in 1993. A 2025 critique of the literature found that a PubMed search returned more than 190 BPC-157 articles, over 80% of which list the same Zagreb lead investigator. In rats, the results are consistently striking: faster healing of transected tendons, crushed muscle, fistulas and stomach lesions.

The best independent summary is a 2025 systematic review in orthopaedic sports medicine. After screening the literature, it included 36 studies: 35 preclinical and one clinical. That ratio is the story of this compound.

What the human evidence shows

There is one randomised, placebo-controlled trial, and it was never fully published. In the mid-2000s, the Croatian drugmaker Pliva tested BPC-157 as an enema in mild-to-moderate ulcerative colitis. All that exists is a conference abstract. FDA reviewers summarised it this year: 53 subjects were randomised to an 80 mg enema or placebo daily for two weeks. The disease activity score fell by 3.2 points on BPC-157 versus 1.6 on placebo, but the confidence interval for the difference between groups crossed zero. In plain terms, the trial did not show a statistically reliable benefit.

Everything else is small and uncontrolled. The FDA’s literature search found five clinical studies in total: rectal enemas in 24 healthy volunteers, the colitis trial, knee injections in 17 people with knee pain, bladder-wall injections in 12 people with interstitial cystitis, and IV infusions in two healthy adults. The last three come from the same Florida clinic, and none of them had a control group.

For the way most people actually use it, there is nothing. The FDA found no human pharmacokinetic data at all after oral, subcutaneous, nasal or transdermal use. In the enema studies, the peptide wasn’t detected in the blood. A Phase 1 trial of oral tablets in Mexico was registered, but no results were ever posted, and the FDA could find no associated publication.

What happened at the FDA

In September 2023, the FDA placed BPC-157 in Category 2, its list of bulk substances that raise significant safety concerns. That effectively stopped US compounding pharmacies from making it.

The reversal came in two steps. On 15 April 2026, the FDA announced it would remove twelve peptides, BPC-157 among them, from Category 2 within seven days, because the parties who had nominated them withdrew their nominations. That was a procedural move, not a new safety finding.

On 23 July, the Pharmacy Compounding Advisory Committee voted 8–6, with one abstention, to recommend adding BPC-157 to the 503A Bulks List. The use it evaluated was ulcerative colitis, which is almost nobody’s reason for buying it. Tendon and injury use was never assessed, because the nomination didn’t contain enough information to evaluate it.

The vote went against the agency’s own reviewers. FDA staff formally proposed not adding BPC-157, citing poor chemical characterisation, missing safety and immunogenicity data, no conclusive evidence of effectiveness, and the existence of approved treatments for ulcerative colitis. One FDA official told the panel, “We’ve never faced a problem of, ‘What is it?’”

The panel itself has drawn scrutiny. Eight of the 14 members were recently appointed under Health Secretary Kennedy, and Reuters reported that six of those appointees operate or work for clinics offering peptide treatments. HHS says every member passed the standard ethics vetting.

What it costs you

No serious adverse events were reported in the human studies, but those studies were tiny and short. The animal data carries signals that rarely make it into marketing. In 28-day injection studies in rats and dogs, FDA reviewers flagged altered clotting times and liver-related signals, including raised ALT. No carcinogenicity studies exist. That gap matters for a compound promoted for its effect on new blood-vessel growth. Whether that effect could feed a tumour is an open, actively argued question in the literature, not a demonstrated risk.

The FDA’s adverse event database holds three reports. In one, a woman using a “research purposes only” BPC-157/TB-500 blend developed diffuse skin and gum darkening, and the same reaction returned when she restarted it. Because it was a blend, the reaction can’t be pinned on either peptide.

The agency’s larger worry is immunogenicity. As a 15-amino-acid peptide injected under the skin, BPC-157 may carry a significant risk of triggering an immune response, amplified by aggregation and impurities. No study has ever measured it.

Where it stands legally

The vote is a recommendation, not a rule. None of the peptides has been added to the 503A Bulks List. The FDA must still decide whether to accept the advice and, if it does, run a proposed rule, a comment period and a final rule before pharmacies can legally compound them. Lawyers in the field put that at eight to twelve months. Until then, compounding remains outside the legal exemption, and BPC-157 is not a legal dietary supplement ingredient.

For athletes, nothing changed. BPC-157 is prohibited at all times under the S0 category of WADA’s 2026 Prohibited List, and a Canadian athlete has received a four-year ban based on non-analytical evidence of BPC-157 and TB-500 use.

What’s in the vial

This is where the FDA review is most damning. The agency found that multiple salts and derivatives, including different active molecules, are sold under the same “BPC-157” name, so a patient can receive a different substance from the one ordered. Both nominators asked for one form of the peptide but supplied certificates of analysis for the other. Across the market, most certificates of analysis report only a purity figure, with no impurity limits and often no endotoxin testing. A “99% pure” label does not tell you what the other 1% is, or whether the vial is sterile.

What nobody knows yet

Whether BPC-157 works in humans for anything. What dose reaches the blood after a subcutaneous injection. Whether it triggers antibodies. What happens over months of use. Whether the FDA will accept its panel’s advice. Every one of those questions is answerable with standard trials, and in 33 years none has been run to completion and published.

Evidence grade: Animal only

A large, consistent and largely single-lab animal literature. The only randomised human trial is an unpublished abstract that showed no statistically reliable effect, and there is no human data for injected use.

Sources: FDA Briefing Document, BPC-157-Related Bulk Drug Substances, Pharmacy Compounding Advisory Committee, 23–24 July 2026 (FDA); Vasireddi et al., HSS Journal 2025 (PubMed 40756949); Józwiak et al., Pharmaceuticals 2025, and reply to Sikiric et al.; Lee & Burgess, Altern Ther Health Med 2025 (PubMed 40131143); FDA 503A Categories update, 15 April 2026; RAPS, 23 July 2026; NBC News and Reuters, 23 July 2026; WADA 2026 Prohibited List.

Disclosure: Peptide Curious’s publishers work commercially in this field. One of them operates a peptide brand whose product line includes BPC-157. Nothing in this dispatch links to any product or service. See our disclosure. Nothing here is medical advice, and nothing here is a recommendation to use any compound.

← All dispatches